Form 4: Axsome COO Sells Shares After Option Exercise

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, exercised stock options and subsequently sold 10,000 common shares for a weighted average price of $115.96 per share.

Summary

• Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, Inc., exercised 10,000 stock options on September 22, 2025.
• These options had an exercise price of $2.85 per share and were set to expire due to reaching their 10-year expiration date.
• Immediately following the exercise, Mr. Jacobson sold all 10,000 newly acquired common shares.
• The shares were sold at a weighted average price of $115.96 per share, with individual sales ranging from $115.11 to $116.55.
• Both the exercise and sale were conducted under a pre-approved Rule 10b5-1 trading plan, which is now completed.
• Following these transactions, Mr. Jacobson directly owns 35,378 stock options and no common stock from this specific transaction.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise of expiring stock options and the subsequent sale of shares under a pre-approved 10b5-1 plan. This is a personal financial event for the executive and does not reflect directly on the company's operational performance or future prospects. The significant profit from the options exercise is positive for the individual but neutral for the company's sentiment.

Positives

• The transactions were executed under a pre-approved Rule 10b5-1 plan, indicating a pre-scheduled, non-discretionary sale.
• The sale price of $115.96 per share is significantly higher than the exercise price of $2.85 per share, indicating a substantial gain for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Risks

• Potential for negative market perception due to an insider selling a significant number of shares, even if the transaction was pre-planned and for personal financial management.

Future Outlook

This filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategy. It solely reports an insider transaction.

Management Comments

• "Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options."
• "Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed."
• "Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information directly related to broader industry trends or competitors. It reflects an individual executive's personal financial planning.

Comparison to Industry Standards

• This filing reports an individual insider transaction, which is not typically compared to industry-wide financial performance benchmarks.
• The transaction itself, involving the exercise of expiring options and subsequent sale under a 10b5-1 plan, is a standard practice for executives managing their equity compensation.

Stakeholder Impact

• Shareholders: May perceive the insider sale as a slight negative, though the pre-approved 10b5-1 plan mitigates concerns about discretionary timing. The executive's direct equity ownership from this specific grant is reduced.

Next Steps

• No specific future actions or milestones for the company are mentioned in this filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the Chief Operating Officer exercised expiring stock options and subsequently sold the acquired shares under a pre-approved 10b5-1 plan. While the executive realized a significant gain, this transaction is a personal financial event and does not provide new information about Axsome Therapeutics' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not present a compelling reason to alter an existing investment thesis.

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Mark L. Jacobson, Chief Operating Officer, 10b5-1 Plan